645 filings
10-Q
2024 Q1
VXRT
Vaxart Inc
Quarterly report
13 May 24
4:11pm
8-K
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
8-K
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
ARS
2023 FY
VXRT
Vaxart Inc
29 Apr 24
Annual report to shareholders
4:39pm
DEFA14A
VXRT
Vaxart Inc
29 Apr 24
Additional proxy soliciting materials
4:38pm
S-8
fwec6 90mwok997
14 Mar 24
Registration of securities for employees
4:56pm
8-K
2dk0h
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
eitt7 9ymu
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
83ta6keq2bbc b7txbky
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K
wvny1yp 771sptpwtle
15 Feb 24
Other Events
4:10pm
8-K/A
y28o jrbw4xs1p8
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
buvzx
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
frs95o xk2ieih0
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
z4r744xwttp
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
3fv3a
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
wumjxx9cq9 8c44utv
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm